SCHEMBL5459324

SCHEMBL5459324

CCOC(=O)N1CCN(C(=O)Nc2sc3c(c2C(N)=O)CCOC3)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.55
TLR2 O60603 5/20 0.52
TLR1 Q15399 1/20 0.52
KMT2A Q03164 4/20 0.49
MAPT P10636 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ATM Q13315 1/20 0.47
CNR2 P34972 2/20 0.47
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
POLB P06746 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457693 0.85 KMT2A (0.60) CFTRKMT2AALDH1A1KDM4EALOX15
SCHEMBL5458266 0.85 CFTR (0.50) CFTRKMT2AMAPTNPSR1MEN1
SCHEMBL5450926 0.84 POLB (0.64) CFTRKMT2AMAPTALDH1A1KDM4E
SCHEMBL5449174 0.83 CFTR (0.55) CFTRKMT2AMAPTMEN1ALDH1A1
SCHEMBL5453343 0.79 CFTR (0.54) CFTRKMT2ACNR2CNR1PTPRC
SCHEMBL5451710 0.76 CFTR (0.58) CFTRKMT2AMAPTNPSR1MEN1
SCHEMBL8290653 0.76 CFTR (0.67) CFTRKMT2AMAPTMEN1ALDH1A1
SCHEMBL5449075 0.76 CFTR (0.66) CFTRKMT2AMAPTMEN1ALDH1A1
SCHEMBL5477448 0.75 ALDH1A1 (0.64) CFTRKMT2AMAPTMEN1ALDH1A1
SCHEMBL5462741 0.75 CFTR (0.62) CFTRKMT2ANPSR1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885TLR2 3061/4885TLR1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.